Le mode conseil est activé Arrêter

ANI Pharmaceuticals, ordinary share
US00182C1036, ANIP

Ajouter une action à la Liste de suivi
Sélectionnez tout Réinitialiser tout
ANI Pharmaceuticals, pays — États-Unis
Aucunes données de trading
Représentation des données graphique | tableau
Source d'information - PJSC "MOEX". Toute autre diffusion des informations MOEX est interdite sans l'accord préalable de PJSC "MOEX".
Source d'information - PJSC "MOEX". Toute autre diffusion des informations MOEX est interdite sans l'accord préalable de PJSC "MOEX".
de
à
ADD-IN
Add-in Cbonds API
bond data api
Il faut s'enregistrer
Envoyer la demande d'accès accès
Plus de 2 500 éléments ont été trouvés, veuillez préciser votre demande
Pas de données sur la période choisie

Dernières cotations

explorer la base de données la plus complète

800 000

obligations globalement

Plus de 400

sources de prix

80 000

actions

9 000

ETF

suivre votre portefeuille de la manière la plus efficace
screener d'obligations
liste de surveillance
Excel ADD-IN
Obtenir l'accès

Émetteur

Profil
ANI Pharmaceuticals, Inc., an integrated specialty pharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals. The company manufactures oral solid dose products, as well as liquids and topicals, narcotics, and potent products; and Lithobid ...
ANI Pharmaceuticals, Inc., an integrated specialty pharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals. The company manufactures oral solid dose products, as well as liquids and topicals, narcotics, and potent products; and Lithobid lithium carbonate extended release tablets. Its targeted areas of product development include narcotics, oncolytics, hormones and steroids, and complex formulations involving extended release and combination products.
Montrer tout Cacher
  • Emetteur
  • Nom complet de l'emprunteur / émetteur
    ANI Pharmaceuticals, Inc.
  • Secteur (industrie)
    Production de médicaments et biotechnologies

IPO/SPO

  • Le type de placement
    SPO | Terminé
  • Le type d'abonnement
    Ouverte
  • La bourse de placement
    NASDAQ
  • Ticker 
    ANIP
  • Le placement
    05.11.2021
  • La période de blocage
    180
  • La quantité des titres
    1.500.000
  • Le montant des fonds levés
    75 mln USD
  • La part du placement
    10,53%
  • Le prix final de placement
    50 USD
  • Variation de prix à compter de la date de placement
    34,5%
  • Par capitalisation
    712,04 mln USD

Rapports IFRS / US GAAP

2023
I q ang
II q ang
III q ang
IV q ang
2022
I q ang
II q ang
III q ang
IV q ang
2021
I q ang
II q ang
III q ang
IV q ang
2020
I q ang
II q ang
III q ang
IV q ang
2019
I q ang
II q ang
III q ang
IV q ang
2018
I q ang
II q ang
III q ang
IV q ang
2017
I q ang
II q ang
III q ang
IV q ang
2016
I q ang
II q ang
III q ang
IV q ang
2015
I q ang
II q ang
III q ang
IV q ang
2014
IV q ang
Afficher tout Masquer
Il faut s'enregistrer
Envoyer la demande d'accès accès

Indices contenant l’action

Indicateurs

Actualités

17/04/2024 ANI Pharmaceuticals: Results Of Operations And Financial Condition, Regulation Fd Disclosure, Exhibits
12/03/2024 ANI Pharmaceuticals: Results Of Operations And Financial Condition, Regulation Fd Disclosure, Exhibits
29/02/2024 ANI Pharmaceuticals: Results Of Operations And Financial Condition, Exhibits
21/02/2024 Moody's Investors Service revised outlook on ANI Pharmaceuticals to positive and affirmed at "B2" (LT- foreign currency) credit rating
21/02/2024 Moody's revises ANI Pharmaceuticals' outlook to positive; affirms B2 CFR (Rating action commentary)
Toutes les actualités de l'organisation

Détenteurs

Leaders de l'industrie

Vous devez vous inscrire pour y accéder.